What was the consensus EPS estimate for Q2 2025 and how does the reported adjusted EPS of $0.30 compare? | AMN (Aug 07, 2025) | Candlesense

What was the consensus EPS estimate for Q2 2025 and how does the reported adjusted EPS of $0.30 compare?

Answer

The news release you provided does not include the consensus (analyst) earnings‑per‑share (EPS) estimate for AMN Healthcare’s second‑quarter 2025 results.

Because the consensus EPS figure isn’t supplied in the information you gave, we can’t directly compare it to the company‑reported adjusted EPS of $0.30 per share.

What this means for you

Item Value (from the press release)
Reported adjusted EPS (Q2 2025) $0.30 per share
Consensus EPS estimate (Q2 2025) Not disclosed in the provided excerpt

How to interpret the comparison (once the consensus estimate is known)

  • If the consensus estimate were **higher than $0.30 (e.g., $0.35 or $0.40), the company’s adjusted EPS would be **below analyst expectations, suggesting a potential disappointment to investors and a likelihood that the stock price could face downward pressure, all else equal.

  • If the consensus estimate were **lower than $0.30 (e.g., $0.25 or $0.20), the company’s adjusted EPS would be **above expectations, which generally would be viewed positively by the market, potentially supporting a price uptick.

  • If the consensus estimate were **about the same as $0.30 (within a few cents), the result would be considered in‑line with expectations, and the market reaction would likely hinge on other factors (revenue growth, cash flow, guidance, etc.) rather than the EPS number alone.


What you can do next

  1. Locate the consensus estimate – This is typically available from:

    • Financial data platforms (Bloomberg, Refinitiv, FactSet, Zacks, Yahoo! Finance, etc.).
    • Brokerage research notes that published the consensus prior to the earnings release.
    • Earnings preview articles (often posted a few days before the earnings date) that summarize analyst expectations.
  2. Compare the numbers – Once you have the consensus EPS figure:

    • Subtract it from the reported adjusted EPS ($0.30) to compute the absolute and percentage deviation.
    • Consider the broader context (revenue beat, profit margins, guidance) to assess whether the EPS difference is likely to be a significant market driver.

Summary: The provided news excerpt does not specify a consensus EPS estimate for Q2 2025, so we cannot directly compare it to the reported adjusted EPS of $0.30 per share. You’ll need to retrieve the consensus estimate from the sources listed above to make a full comparison.

Other Questions About This News

What macro‑economic factors (e.g., labor market conditions, healthcare spending, staffing demand) could influence future results? How did the company’s operating margin change year‑over‑year and what cost drivers are influencing it? Did the company provide guidance for Q3 2025 revenue, EPS, and Adjusted EBITDA, and how does that compare to analyst expectations? What contributed to the Adjusted EBITDA of $58.3 million and how does this compare to previous quarters? What were the main drivers behind the GAAP loss of $3.02 per share? What are the implications of the GAAP loss versus the positive adjusted EPS for valuation metrics (P/E, EV/EBITDA), and how might investors re‑price the stock? How does AMN’s Q2 performance compare to peers such as Cross Country Healthcare, Envision Healthcare, or other staffing firms? How did AMN Healthcare’s Q2 2025 revenue of $658 million compare to consensus estimates? Did AMN disclose any changes to its capital allocation strategy—share repurchases, dividends, or acquisitions? Did the earnings release mention any regulatory or policy changes that may affect revenue or margins? What changes in key operational metrics (e.g., placements, revenue per employee, utilization rates) were highlighted that could affect future performance? What is the current analyst consensus on the stock after the release—upgrades, downgrades, or rating changes? What full‑year 2025 guidance did AMN give for revenue, profit and cash flow, and how does it align with market expectations? Are there any updates to the company’s debt profile, cash balance, or liquidity position? What was the immediate market reaction (price movement, volume) to the release and how does that compare to typical earnings reactions for AMN?